Short answer
Anika Therapeutics, Inc. (ANIK) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $31M (up 10.0% year over year) with net income of −$311,000.
Q3 2026 key financials · XBRL
- Revenue
- $31M
- +10.0% YoY · −6.2% QoQ
- Net income
- −$311,000
- +86.6% YoY · −109.4% QoQ
- Operating margin
- -2.3%
- Gross margin
- 61.6%
- EPS (diluted)
- −$0.02
- +87.5% YoY · −108.3% QoQ
Source: XBRL data from the Anika Therapeutics, Inc. (ANIK) Q3 2026 10-Q on SEC EDGAR. USD.
Anika Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $30.6M, up 10% YoY from $27.8M, driven by Commercial Channel growth
- Gross margin 62% vs 56% YoY, with net loss $0.3M vs $3.2M
- Best segment Commercial Channel revenue $14.0M, up 17%; Integrity sales supported regenerative growth
- Cash $45.0M vs $57.5M at December 31, 2025; operating cash flow $2.8M vs $6.6M
- Hyalofast PMA not approvable; Cingal NDA submission targeted by December 31, 2027
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Carried-forward business risk: disclosed risks could materially affect future results
- Carried-forward uncertainty risk: unknown or currently immaterial risks could materially harm operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anika Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.